Related Experiment Video

Updated: Jun 13, 2026

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
08:32

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus

Published on: January 17, 2025

Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus

Adam Frymoyer1, Adam L Hersh, Zlatan Coralic

  • 1Division of Clinical Pharmacology, Department of Medicine, University of California, San Francisco, California 94143-0912, USA. frymoyera@peds.ucf.edu

Clinical Therapeutics
|April 20, 2010
PubMed
Abstract

Insights

Current vancomycin doses for pediatric invasive MRSA infections may not reach the target AUC(0-24)/MIC >400. Increasing vancomycin dosage to 60 mg/kg/d significantly improves the likelihood of achieving this critical pharmacodynamic target in children.

Area of Science:

  • Pediatric Infectious Diseases
  • Pharmacokinetics and Pharmacodynamics
  • Antimicrobial Stewardship

Background:

  • Invasive methicillin-resistant Staphylococcus aureus (MRSA) infections are rising in children.
  • A vancomycin AUC(0-24)/MIC index >400 is crucial for effective treatment in adults.
  • Current pediatric vancomycin dosing guidelines lack data on achieving this target.

Purpose of the Study:

  • To evaluate if current pediatric vancomycin doses achieve the target AUC(0-24)/MIC >400.
  • To determine optimal vancomycin dosing for invasive MRSA infections in children.

Main Methods:

  • Monte Carlo simulations (n=5000) predicted vancomycin AUC(0-24)/MIC.
  • Simulations used dosages from 40-70 mg/kg/d and literature-based pediatric vancomycin clearance.
  • MRSA MIC distribution data from a pediatric hospital (n=180) were incorporated.

Main Results:

  • The recommended 40 mg/kg/d dose achieved the target in only 58%-66% of simulated pediatric patients.
  • Increasing vancomycin to 60 mg/kg/d increased target achievement to 88%-98%.
  • Lower doses were more sensitive to MIC variability.

Conclusions:

  • The standard 40 mg/kg/d vancomycin dose is insufficient for consistently reaching the AUC(0-24)/MIC >400 target in pediatric invasive MRSA.
  • A vancomycin dosage of 60 mg/kg/d is recommended to optimize pharmacodynamic target attainment in children.

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).